The temporary technical problem in the data network connections
A temporary technical problem occurred in the data network connections of Docrates Cancer Center. We apologise for any delays caused...
Read moreMon–Fri 8–16
In January 2017, we were the first health care provider in Finland to use 177-lutetium-PSMA isotope therapy in the treatment of advanced prostate cancer, which enables destroying metastases outside the bones efficiently without any severe adverse effects.
Before the treatment, we carry out a diagnostic PET scan using F-PSMA tracers to ensure that 177-lutetium-PSMA uptake occurs in the metastases.
177-lutetium-PSMA therapies are administered intravenously, and its their most common side effect is a dry mouth. Depending on the individual, the treatment is typically performed 2–6 times approximately every 4–6 weeks (177-lutetium-PSMA).
The multidisciplinary team in charge of peptide-receptor therapies at Docrates Cancer Center is led by Chief Physician in Nuclear Medicine Jukka Kemppainen.
The VISION study results* were presented in ESMO2021 conference: the results showed that treatment with 177-lutetium-PSMA significantly improved overall survival (OS) in patients with PSMA-positive metastatic castration-resistant prostate cancer.
*Publiced in NEJM September 2021
A temporary technical problem occurred in the data network connections of Docrates Cancer Center. We apologise for any delays caused...
Read moreHannu Nurmio was aware that prostate cancer is the most common cancer in older men. However, after the diagnosis was confirmed,...
Early detection of colorectal cancer is crucial for successful treatment. If diagnosed early, up to 90% of cancers can be...
Docrates Cancer Center is the first service provider in the Nordic region to launch a new experimental alpha radiation treatment...
Contact us!
Mon-Thu 8:00-18:00, Fri 8:00-16:00